Prevalence and significance of Hepatitis B reverse transcriptase mutants in different disease stages of untreated patients

Liver International

Volumn 32, Issue 10, 2012, Pages 1535-1542

  Zheng, Jinxin ^a   Zeng, Zheng ^a   Zhang, Duyi ^a   Yu, Yanyan ^a   Wang, Fang ^a   Pan, Calvin Q ^b,c  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c New Discovery   (United States)

Author keywords

Clinical outcomes; Hepatitis B virus; Mutations; Naive; Reverse transcriptase

Indexed keywords

RNA DIRECTED DNA POLYMERASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PREVALENCE; VIRUS RESISTANCE;

AGE FACTORS; BASE SEQUENCE; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CHINA; DNA PRIMERS; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; POLYMERASE CHAIN REACTION; PREVALENCE; RNA-DIRECTED DNA POLYMERASE; SEQUENCE ANALYSIS, DNA; STATISTICS, NONPARAMETRIC;

EID: 84867096252     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02859.x     Document Type: Article

References (27)

1. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002; 2: 395-403.
2. Chen DS. From hepatitis to hepatoma: Lessons from type B viral hepatitis. Science 1993; 262: 369-70.
3. Lok AS, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50: 661-62.
4. Wright TL. Clinical trial results and treatment resistance with lamivudine in hepatitis B. Semin Liver Dis 2004; 24(Suppl 1): 31-36.
5. Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006; 44: 422-31.
6. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 254-65.
7. Yang H, Westland CE, Delaney WE 4th, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002; 36: 464-73.
8. Sheldon J, Rodès B, Zoulim F, Bartholomeusz A, Soriano V. Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat 2006; 13: 427-34.
9. Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 2001; 34: 584-86.
10. Kirishima T, Okanoue T, Daimon Y, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol 2002; 37: 259-65.
11. Matsuda M, Suzuki F, Suzuki Y, et al. YMDD Mutants in Patients With Chronic Hepatitis B before Treatment Are Not Selected by Lamivudine. J Med Virol 2004; 74: 361-66.
12. Heo J, Cho M, Kim HH, et al. Detection of YMDD Motif Mutants by Oligonucleotide Chips in Lamivudine-Untreated Patients with Chronic Hepatitis B Virus Infection. J Korean Med Sci 2004; 19: 541-46.
13. Huang ZM, Huang QW, Qin YQ, et al. YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines. World J Gastroenterol 2005; 11: 867-70.
14. Lee CZ, Lee HS, Huang GT, Yang PM, Sheu JC. Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients before and after lamivudine treatment. World J Gastroenterol 2006; 12: 5301-05.
15. Akarsu M, Sengonul A, Tankurt E, et al. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay. J Gastroenterol Hepatol 2006; 21: 1783-88.
16. Han Y, Huang LH, Liu CM, et al. Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients. J Gastroenterol Hepatol 2009; 24: 1417-23.
17. Nguyen MH, Keeffe EB. Chronic hepatitis B: Early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J Viral Hepat 2009; 16: 149-55.
18. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006; 44: 1656-65.
19. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-14.
20. Zeng Z, Guan L, An P, et al. A population-based study to investigate host genetic factors associated with hepatitis B infection and pathogenesis in the Chinese population. BMC Infect Dis 2008; 8: 1.
21. Borroto-Esoda K, Miller MD, Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol 2007; 47: 492-98.
22. Liu BM, Li T, Xu J, et al. Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naive Chinese patients. Antiviral Res 2010; 85: 512-19.
23. Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33: 751-57.
24. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007; 24: 1596-99.
25. Bartholomeusz A, Tehan BG, Chalmers DK. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir Ther 2004; 9: 149-60.
26. Echevarria JM, Avellón A. Hepatitis B virus genetic diversity. J Med Virol 2006; 78(Suppl. 1): S36-S42.
27. Ogura Y, Kurosaki M, Asahina Y, et al. Prevalence and significance of naturally occurring mutations in the surface and polymerase genes of hepatitis B virus. J Infect Dis 1999; 180: 1444-51.